[Skip to Navigation]
Views 2,779
Citations 0
JAMA Dermatology Clinicopathological Challenge
December 9, 2020

Annular Plaques in a Woman Receiving Systemic Immunotherapy

Author Affiliations
  • 1David Geffen School of Medicine, University of California, Los Angeles
  • 2Division of Dermatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles
JAMA Dermatol. 2021;157(2):224-225. doi:10.1001/jamadermatol.2020.4810

A woman in her 70s with recurrent primary peritoneal carcinoma receiving pembrolizumab and ipilimumab presented to the Division of Dermatology with a pruritic rash that had been ongoing for 2 weeks. The rash started as an erythematous papule on her right arm 2 months after initiation of a new immunotherapy regimen, then gradually enlarged and spread to involve both legs (Figure, A and B). She denied any new systemic symptoms associated with onset of the rash. A recent trial of oral terbinafine for possible tinea corporis yielded no improvement. Physical examination revealed erythematous annular plaques without scale on her right arm and bilateral legs. A 4-mm punch biopsy was obtained from the patient’s right arm (Figure, C and D), and she was prescribed fluocinonide, 0.05%, ointment. She returned to the clinic 3 weeks later with resolution of pruritus but enlarging lesions. Her last dose of ipilimumab was 2 months prior, and she was scheduled to receive pembrolizumab with doxorubicin, carboplatin, and prednisone for treatment of her underlying malignant tumor. For management of her rash, the patient was prescribed betamethasone dipropionate, 0.05%, ointment (augmented).

Add or change institution
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words